3-溴丙基-2-乙酰氧基苯甲酸酯 | 204632-98-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴丙基-2-乙酰氧基苯甲酸酯
• 英文名称: 3-bromopropyl 2-acetoxybenzoate
• 英文别名: 3-Bromopropyl 2-(acetyloxy)benzoate；3-bromopropyl 2-acetyloxybenzoate
• CAS: 204632-98-4
• 化学式: C₁₂H₁₃BrO₄
• 分子量: 301.137
• InChiKey: DFBXNPRZYSGLHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-溴丙基-2-乙酰氧基苯甲酸酯 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 3-azidopropyl 2-acetoxybenzoate
  参考文献：
  名称：

  The first examples of ilexgenin A hybrids as a new class of multi-potent, anti-platelet agents

  摘要：

  Seventeen novel ilexgenin A hybrids (IA-aspirin) and (IA-NO), as donor hybrids (IA-NO will release NO in vivo and function as NO donor), were designed and synthesized in order to develop new multi-targeting agents for the treatment of platelet disorders. Their in vitro activities against ADP, AA and thrombin were evaluated. As a result, IA hybrids achieved substantial increases in the three tested pathways compared with IA. Encouragingly, the most potent hybrid compounds 6d and 14d displayed about 8-fold higher potency than aspirin, and 3-fold higher potency than the simultaneous administration of aspirin and IA in inhibiting ADP-induced aggregation with IC50 values of 0.15 mmol/L and 0.14 mmol/L, respectively. The results suggest these IA hybrids are good candidates for multi-target therapies, and especially, may be considered as promising ADP agonists. (C) 2013 Fei-Hua Wu and Jing-Yu Liang. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2013.05.021
• 作为产物：
  描述：

  1,3-二溴丙烷 、 阿司匹林 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-溴丙基-2-乙酰氧基苯甲酸酯
  参考文献：
  名称：

  The first examples of ilexgenin A hybrids as a new class of multi-potent, anti-platelet agents

  摘要：

  Seventeen novel ilexgenin A hybrids (IA-aspirin) and (IA-NO), as donor hybrids (IA-NO will release NO in vivo and function as NO donor), were designed and synthesized in order to develop new multi-targeting agents for the treatment of platelet disorders. Their in vitro activities against ADP, AA and thrombin were evaluated. As a result, IA hybrids achieved substantial increases in the three tested pathways compared with IA. Encouragingly, the most potent hybrid compounds 6d and 14d displayed about 8-fold higher potency than aspirin, and 3-fold higher potency than the simultaneous administration of aspirin and IA in inhibiting ADP-induced aggregation with IC50 values of 0.15 mmol/L and 0.14 mmol/L, respectively. The results suggest these IA hybrids are good candidates for multi-target therapies, and especially, may be considered as promising ADP agonists. (C) 2013 Fei-Hua Wu and Jing-Yu Liang. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2013.05.021

文献信息

• Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitro-aspirins
  作者：John F. Gilmer、Louise M. Moriarty、John M. Clancy

  DOI：10.1016/j.bmcl.2007.03.009

  日期：2007.6

  compounds potentially capable of releasing both aspirin and nitric oxide in vivo. A series of nitrate-bearing alkyl esters of aspirin were prepared based on the choline ester template preferred by human plasma butyrylcholinesterase. The degradation kinetics of the compounds were followed in human plasma solution. All compounds underwent hydrolysis rapidly (t(1/2) approximately 1min) but generating

  本文中，我们探讨了硝基阿司匹林的一些设计，这些化合物可能在体内释放阿司匹林和一氧化氮。基于人血浆丁酰胆碱酯酶优选的胆碱酯模板，制备了一系列阿司匹林的含硝酸烷基酯。在人血浆溶液中跟踪化合物的降解动力学。所有化合物均迅速水解（t（1/2）约1分钟），但仅生成相应的水杨酸硝基酯。一个例外是，N-丙基，N-硝基氧乙基氨基乙醇酯以摩尔计产生9.2％的阿司匹林，表明如果可以对活化酶的要求进行适当的认知，就可以实现硝基阿司匹林的目标。即使阿司匹林的释放量很低，
• Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin
  作者：Clara Cena、Marco L. Lolli、Loretta Lazzarato、Elena Guaita、Giuseppina Morini、Gabriella Coruzzi、Stuart P. McElroy、Ian L. Megson、Roberta Fruttero、Alberto Gasco

  DOI：10.1021/jm020969t

  日期：2003.2.1

  aspirin is joined by an ester linkage to furoxan moieties, with different ability to release NO, were synthesized and tested for NO-releasing, antiinflammatory, antiaggregatory, and ulcerogenic properties. Related furazan derivatives, aspirin, its propyl ester, and its gamma-nitrooxypropyl ester were taken as references. All the products described present an antiinflammatory trend, maximized in derivatives

  合成了一系列新的非甾体抗炎药，其中阿司匹林通过酯键连接到具有不同释放NO能力的呋喃喃部分上，并测试了其释放NO，抗炎，抗聚集和致溃疡的特性。相关的呋喃山衍生物，阿司匹林，其丙基酯和其γ-硝基氧丙基酯均作为参考。所描述的所有产品均表现出抗炎趋势，在衍生物12、16和17中达到最大，主要由于其酯类性质，它们没有急性胃毒性，并且显示出主要由其释放NO的能力决定的抗血小板活性。它们在人血清中不具有阿司匹林前药的作用。
• Synthesis and in vitro evaluation of triphenylphosphonium derivatives of acetylsalicylic and salicylic acids: structure-dependent interactions with cancer cells, bacteria, and mitochondria
  作者：Olga V. Tsepaeva、Taliya I. Salikhova、Leysan R. Grigor’eva、Denis V. Ponomaryov、Trinh Dang、Rezeda A. Ishkaeva、Timur I. Abdullin、Andrey V. Nemtarev、Vladimir F. Mironov

  DOI：10.1007/s00044-020-02674-6

  日期：2021.4
• The first examples of ilexgenin A hybrids as a new class of multi-potent, anti-platelet agents
  作者：Li-Ping Lin、Fei-Hua Wu、Jing-Yu Liang

  DOI：10.1016/j.cclet.2013.05.021

  日期：2013.8

  Seventeen novel ilexgenin A hybrids (IA-aspirin) and (IA-NO), as donor hybrids (IA-NO will release NO in vivo and function as NO donor), were designed and synthesized in order to develop new multi-targeting agents for the treatment of platelet disorders. Their in vitro activities against ADP, AA and thrombin were evaluated. As a result, IA hybrids achieved substantial increases in the three tested pathways compared with IA. Encouragingly, the most potent hybrid compounds 6d and 14d displayed about 8-fold higher potency than aspirin, and 3-fold higher potency than the simultaneous administration of aspirin and IA in inhibiting ADP-induced aggregation with IC50 values of 0.15 mmol/L and 0.14 mmol/L, respectively. The results suggest these IA hybrids are good candidates for multi-target therapies, and especially, may be considered as promising ADP agonists. (C) 2013 Fei-Hua Wu and Jing-Yu Liang. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.